Humacyte annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
Humacyte's debt-to-assets ratio was 0.56 for fiscal 2025.
View full Humacyte company overview| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.56 | −0.03 | −5.54% |
| 2024 | 2024-12-31 | 0.59 | 0.14 | +30.20% |
| 2023 | 2023-12-31 | 0.45 | 0.35 | +324.65% |
| 2022 | 2022-12-31 | 0.11 | −0.08 | −43.17% |
| 2021 | 2021-12-31 | 0.19 | −0.08 | −30.62% |
| 2020 | 2020-12-31 | 0.27 | — | — |
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.48 | −0.12 | −20.49% |
| Q1 2026 | 2026-03-31 | 0.60 | 0.09 | +17.86% |
| Q4 2025 | 2025-12-31 | 0.56 | −0.03 | −5.54% |
| Q3 2025 | 2025-09-30 | 0.55 | −0.14 | −20.11% |
| Q2 2025 | 2025-06-30 | 0.60 | 0.04 | +6.86% |
| Q1 2025 | 2025-03-31 | 0.51 | 0.03 | +6.71% |
| Q4 2024 | 2024-12-31 | 0.59 | 0.14 | +30.20% |
| Q3 2024 | 2024-09-30 | 0.69 | 0.31 | +81.99% |
| Q2 2024 | 2024-06-30 | 0.56 | 0.23 | +68.38% |
| Q1 2024 | 2024-03-31 | 0.47 | 0.36 | +308.08% |
| Q4 2023 | 2023-12-31 | 0.45 | 0.35 | +324.65% |
| Q3 2023 | 2023-09-30 | 0.38 | 0.28 | +285.23% |
| Q2 2023 | 2023-06-30 | 0.34 | 0.12 | +56.20% |
| Q1 2023 | 2023-03-31 | 0.12 | −0.09 | −42.42% |
| Q4 2022 | 2022-12-31 | 0.11 | −0.08 | −43.17% |
| Q3 2022 | 2022-09-30 | 0.10 | −0.05 | −32.40% |
| Q2 2022 | 2022-06-30 | 0.21 | — | — |
| Q1 2022 | 2022-03-31 | 0.20 | — | — |
| Q4 2021 | 2021-12-31 | 0.19 | −0.08 | −30.62% |
| Q3 2021 | 2021-09-30 | 0.15 | — | — |
| Q4 2020 | 2020-12-31 | 0.27 | — | — |
Over the last five fiscal years, Humacyte's debt-to-assets ratio increased from 0.27 to 0.56, a change of 0.29. The latest reported quarter, Q2 2026, shows 0.48.
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗